GlassScriptPhysician profile
Mark R Fesen
NPI 1639149545
$10,488.21
in general payments reported to CMS, 2019-2025
76 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $387 · 2021: $1,328 · 2022: $1,306 · 2023: $1,909 · 2024: $1,896 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,340 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,339.98 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $805.33 | 2019-2025 | |
| Pfizer INC. | $554.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $501.35 | 2019-2025 | Enhertu, Imfinzi |
| Amgen INC. | $473.60 | 2019-2023 | Lumakras |
| Celgene Corporation | $463.30 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
| Genentech USA, INC. | $433.81 | 2019-2025 | Lunsumio, Polivy, Venclexta |
| Janssen Biotech, INC. | $406.52 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Tersera Therapeutics LLC | $376.42 | 2023-2025 | Zoladex, Xermelo, Quzyttir |
| Lilly USA, LLC | $348.82 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $344.35 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $331.98 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $310.53 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $259.66 | 2019-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $247.51 | 2019-2024 | |
| Abbvie INC. | $235.26 | 2021-2025 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $228.16 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $227.97 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $224.84 | 2023-2025 | Myrisk, Precisetumor |
| Sobi, INC | $217.63 | 2022-2025 | |
| Emd Serono, INC. | $210.44 | 2022-2024 | Bavencio |
| Incyte Corporation | $201.84 | 2021-2025 | Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $194.43 | 2021-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $190.44 | 2023-2025 | Iclusig, Fruzaqla, Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $180.27 | 2021-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $168.98 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $157.63 | 2019-2024 | Opdivo, Opdualag, Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.92 | 2020-2025 | Gilotrif |
| Stemline Therapeutics INC. | $129.63 | 2023-2025 | Orserdu |
| Apellis Pharmaceuticals, INC. | $106.30 | 2022-2025 | Empaveli |
| Karyopharm Therapeutics INC. | $97.74 | 2021-2025 | Xpovio |
| Kite Pharma, INC. | $93.77 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $91.61 | 2022-2025 | Onivyde, Tazverik |
| Sumitomo Pharma America, INC. | $90.01 | 2024-2025 | Orgovyx |
| Verity Pharmaceuticals INC. | $82.26 | 2022-2023 | Trelstar |
| Exelixis INC. | $75.19 | 2019-2024 | Cabometyx |
| Mylan Institutional INC. | $74.65 | 2022-2023 | Ogivri, Fulphila |
| Recordati_rare_diseases_inc. | $68.15 | 2025 | Sylvant |
| Iovance Biotherapeutics, INC. | $64.73 | 2024-2025 | Amtagvi |
| Array Biopharma INC | $59.32 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Kyowa Kirin, INC. | $59.28 | 2020-2025 | |
| Bio Products Laboratory USA, INC. | $50.50 | 2019-2023 | Gammaplex, Coagadex |
| Springworks Therapeutics, INC. | $49.26 | 2024-2025 | Ogsiveo |
| Seagen INC. | $48.93 | 2020-2023 | Tukysa |
| Eisai INC. | $48.52 | 2019-2024 | |
| Adaptive Biotechnologies Corporation | $48.43 | 2024-2025 | Clonoseq |
| Spectrum Pharmaceuticals INC. | $45.82 | 2023-2025 | Rolvedon |
| Integra Lifesciences Corporation | $43.89 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Genmab U.S., INC. | $43.86 | 2023-2024 | Tivdak |
| Sun Pharmaceutical Industries INC. | $43.81 | 2022-2023 | Odomzo, Yonsa |
| Blueprint Medicines Corporation | $41.84 | 2021-2024 | Ayvakit |
| Taiho Oncology, INC. | $38.36 | 2025 | |
| Organon LLC | $36.26 | 2022-2024 | Ontruzant |
| Pharmacosmos Therapeutics INC. | $27.58 | 2021-2022 | |
| Clovis Oncology, INC. | $25.47 | 2020-2021 | |
| Beigene USA, INC. | $24.39 | 2021-2022 | |
| Geron Corporation | $23.94 | 2025 | Rytelo |
| Sirtex Medical INC | $22.07 | 2020-2024 | Sir-Spheres Microspheres |
| Novocure INC. | $21.77 | 2024 | Optune Lua (Novottf-200t), Optune |
| Digestive Care, INC. | $20.49 | 2023 | Pertzye |
| Emmaus Medical, INC. | $20.16 | 2021 | |
| Dova Pharmaceuticals | $19.13 | 2019 | |
| Immunocore Limited | $19.01 | 2025 | Kimmtrak |
| Blue Earth Diagnostics | $18.96 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.00 | 2025 | Danziten |
| Alexion Pharmaceuticals, INC. | $17.84 | 2024 | Ultomiris |
| Acceleron Pharma, INC. | $16.61 | 2020 | |
| Fresenius Kabi USA, LLC | $16.11 | 2025 | Stimufend |
| Legend Biotech USA INC. | $15.31 | 2024 | |
| Rigel Pharmaceuticals, INC. | $15.16 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Cti Biopharma Corp. | $13.67 | 2023 | Vonjo |
| Tesaro, INC. | $13.08 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.96 | 2021 | |
| Puma Biotechnology, INC. | $11.86 | 2021 | |
| Verastem, INC. | $11.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.